Plerixafor: A review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma

Drugs

Volumn 71, Issue 12, 2011, Pages 1623-1647

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Myeloma; Non Hodgkins lymphoma; Plerixafor

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LENALIDOMIDE; PLERIXAFOR; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ALGORITHM; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEUKOCYTOSIS; LYMPHOMA; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTOPENIA; VOMITING;

CHEMOKINE CXCL12; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA; MULTIPLE MYELOMA;

EID: 80052003708     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206040-000000000-00000     Document Type: Review

References (111)

1. Rosenbeck LL, Srivastava S, Kiel PJ. Peripheral blood stem cell mobilization tactics. Ann Pharmacother 2010 Jan; 44 (1): 107-16
2. Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizingmobilization regimens. Bone Marrow Transplant 2011 May; 46 (5): 627-35
3. Vose JM, Ho AD, Coiffier B, et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009 Sep; 50 (9): 1412-21
4. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009 Feb; 43 (3): 181-95
5. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008 Sep; 14 (9): 1045-56
6. Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007 May; 39 (10): 577-88
7. Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 2005; 114 (4): 198-205 (Pubitemid 41567002)
8. Genzyme Corporation. Mozobil (plerixafor injection): US prescribing information [online]. Available from URL: http://www.mozobil.com/document/ Package-Insert.pdf [Accessed 2011 May 12]
9. European Medicines Agency. Mozobil (plerixafor) 20 mg/ml solution for injection: EU summary of product characteristics [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001030/WC500030686.pdf [Accessed 2011 May 12]
10. Fricker SP, Anastassov V, Cox J, et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 2006 Aug 28; 72 (5): 588-96 (Pubitemid 44163295)
11. Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002 Sep 11; 527 (1-3): 255-62 (Pubitemid 35253875)
12. Rosenkilde MM, Gerlach L-O, Jakobsen JS, et al. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem 2004 Jan 23; 279 (4): 3033-41 (Pubitemid 38114296)
13. Wong RSY, Bodart V, Metz M, et al. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 2008 Dec; 74 (6): 1485-95
14. Martin C, Bridger GJ, Rankin SM. Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro . Br J Haematol 2006 Aug; 134 (3): 326-9 (Pubitemid 43990796)
15. Burroughs L, Mielcarek M, Little M-T, et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005 Dec 1; 106 (12): 4002-8 (Pubitemid 41739045)
16. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005 Apr 18; 201 (8): 1307-18 (Pubitemid 40629073)
17. Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006 May 1; 107 (9): 3772-8
18. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003 Oct 15; 102 (8): 2728-30 (Pubitemid 37248839)
19. Hübel K, Liles WC, Broxmeyer HE, et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004 Apr 1; 1 (3): 165-72
20. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004 Mar 15; 22 (6): 1095-102 (Pubitemid 41095043)
21. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005 Sep 1; 106 (5): 1867-74 (Pubitemid 41208607)
22. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion (Paris) 2005 Mar; 45 (3): 295-300 (Pubitemid 40389423)
23. Donahue RE, Jin P, Bonifacino AC, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009 Sep 17; 114 (12): 2530-41
24. Hess DA, Bonde J, Craft TC, et al. Human progenitor cells rapidlymobilized by AMD3100 repopulateNOD/SCIDmice with increased frequency in comparison to cells fromthe same donor mobilized by granulocyte colony stimulating factor. Biol BloodMarrow Transplant 2007 Apr; 13 (4): 398-411 (Pubitemid 46421895)
25. Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009; 11 (8): 992-1001
26. Fruehauf S, Seeger T, Maier P, et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006 Aug; 34 (8): 1052-9 (Pubitemid 44080394)
27. Gaugler B, Arbez J, Frikeche J, et al. Characterization of peripheral blood stem cell grafts mobilized by G-CSF and plerixafor in comparison to G-CSF alone [abstract no. O380]. Bone Marrow Transplant 2011 Apr; 46 Suppl. 1: S61-2
28. Gazitt Y, Freytes CO, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony- stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007 Aug; 16 (4): 657-66 (Pubitemid 47378738)
29. Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progressionfree survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007 Jan; 7 (4): 315-8 (Pubitemid 46408198)
30. Cuzzola M, Spiniello E, Martino M, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor mobilize different cell populations based on immunophenotype and global gene experssion signatures [abstract no. P1082]. Bone Marrow Transplant 2011 Apr; 46 Suppl. 1: S335
31. Lack NA, Green B, Dale DC, et al. A pharmacokineticpharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 2005 May; 77 (5): 427-36 (Pubitemid 40719270)
32. Stewart DA, Smith C, MacFarland R, et al. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009 Jan; 15 (1): 39-46
33. Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008 Nov; 14 (11): 1253-61
34. MacFarland R, Hard ML, Scarborough R, et al. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant 2010 Jan; 16 (1): 95-101
35. Fruehauf S, Ehninger G, Hübel K, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010 Feb; 45 (2): 269-75
36. Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009 Feb; 15 (2): 249-56
37. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colonystimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009 Oct 1; 27 (28): 4767-73
38. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009 Jun 4; 113 (23): 5720-6
39. Micallef IN, Stiff PJ, DiPersio JF, et al. Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009 Dec; 15 (12): 1578-86
40. Stiff PJ, Micallef I, Nademanee AP, et al. Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011 Aug; 17 (8): 1146-53
41. Apperley F, Cook G, Pagliuca A, et al. Efficacy of plerixafor plus G-CSF for stem cell mobilization in patients with multiple myeloma or lymphoma who have failed prior mobilisation: a named patient program (NPP) evaluation. Haematologica 2010 Jun; 95 Suppl. 2: 212
42. Arcaini L, Laszlo D, Rizzi S, et al. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience. Leuk Res 2011 Jun; 35 (6): 712-4
43. Basak GW, Knopinska-Posluszny W, Matuszak M, et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100): Polish compassionate use experience. Ann Hematol 2011 May; 90 (5): 557-68
44. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008 Feb; 41 (4): 331-8 (Pubitemid 351330727)
45. Duarte RF, Shaw BE, Marín P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011 Jan; 46 (1): 52-8
46. Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009 Jun; 43 (12): 909-17
47. Hübel K, Fresen MM, Salwender H, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011; 46 (8): 1045-52
48. Hübel K, Fresen MM, Apperley JF, et al. Plerixafor for stem cell mobilization in Hodgkin, non-Hodgkin, and multiple myeloma patients: a subgroup analysis from the European Compassionate Use Program [abstract no. P1075]. Bone Marrow Transplant 2011 Apr; 46 Suppl. 1: S332
49. Jaksic O, Basic-Kinda S, Maricic I, et al. Effective stem cell mobilization with plerixafor + G-CSF followed by large volume leukapheresis in poor mobilizers: the experience of the Croatian cooperative group for haematologic diseases (KROHEM) [abstract no. P1018]. Bone Marrow Transplant 2010 Mar; 45 Suppl. 2: S321
50. Koristek Z, Folber F, Lysák D, et al. The use of plerixafor in Czech transplant centres [abstract no. P1016]. Bone Marrow Transplant 2010 Mar; 45 Suppl. 2: S320
51. Mohty M, Lefrere F, Caillot D, et al. Plerixafor plus G-CSF can mobilize autologous haematopoietic stem cells from heavily pre-treated patients failing previous mobilization attempts: analysis of the French compassionate use programme [abstract no. P1014]. Bone Marrow Transplant 2010 Mar; 45 Suppl. 2: S319-20
52. Segel E, Sørenson B, d'Amore F, et al. Successful peripheral blood stem cell harvest in mobilization-refractory lymphoma patients [abstract no. P844]. Bone Marrow Transplant 2010 Mar; 45 Suppl. 2: S258
53. Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion (Paris) 2011 May; 51 (5): 968-75
54. Basak GW, Jaksic O, Koristek Z, et al. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol 2011 Jun; 86 (6): 488-95
55. Duarte R, Apperley JF, Basak G, et al. Patients and disease characteristics influencing the outcome of mobilization with plerixafor: large compassionate-use analysis by ECOSM (European Consortium for Stem Cell Mobilization) [abstract no. O377]. Bone Marrow Transplant 2011 Apr; 46 Suppl. 1: S60
56. Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010 Jan; 45 (1): 63-8
57. Shapiro J, Bookout R, Perkins J, et al. Primary plerixafor mobilization in autologous hematopoietic cell transplant candidates at high risk for mobilization failure [abstract no. 131]. 2010 BMT Tandem Meetings; 2010 Feb 24-28; Orlando (FL)
58. Micallef IN, Ho AD, Klein LM, et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2011 Mar; 46 (3): 350-5
59. Horwitz M, Khan T, Long G, et al. Plerixafor given 'just in time' for peripheral blood stem cell mobilization of patiemts with suboptimal response to G-CSF [abstract no. 135]. 2010 BMT Tandem Meetings; 2010 Feb 24-28; Orlando (FL)
60. Douglas KW, Parker AN, Hayden PJ, et al. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplant. Epub 2011 Feb 28
61. DiPersio JF, Bridger G, Calandra G. Effect of plerixafor (AMD 3100) plus G-CSF on tumor cell mobilization among patients with lymphoma [abstract]. Biol Blood Marrow Transplant 2009 Feb; 15 (2 Suppl.): 37
62. Campen CJ, Armstrong EP, Christian JA, et al. Comparative cost-effectiveness of plerixafor plus granulocytecolony stimulating factor versus cyclophosphamide plus granulocyte-colony stimulating factor for autologous peripheral blood stem cell mobilization in patients with non-Hodgkin's lymphoma [abstract no. 129]. 2010 BMT Tandem Meetings; 2010 Feb 24-28; Orlando (FL)
63. Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011 May; 17 (5): 729-36
64. Vishnu P, Roy V, Paulsen A, et al. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion (Paris). Epub 2011 Jun 9
65. Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of 'just-in-time' salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion (Paris). Epub 2011 Apr 14
66. Roberts C, Sabo R, Shickle L, et al. Cost-effective stem cell mobilization: a novel early plerixafor salvage strategy is optimally resource-effective compared to chemotherapy, G-CSF or initial plerixafor strategies [abstract no. O378]. Bone Marrow Transplant 2011 Apr; 46 Suppl. 1: S60-1
67. Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011 Jan; 46 (1): 64-9
68. Costa LJ, Miller AN, Alexander ET, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. BoneMarrow Transplant 2011 Apr; 46 (4): 523-8
69. Abhyankar S, DeJarnette S, Aljitawi O, et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant. Epub 2011 Jul 4
70. Micallef I, InwardsDJ, Dispenzieri. A, et al. A risk adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization [abstract no. 110]. 2010 BMT Tandem Meetings; 2010 Feb 24-28; Orlando (FL)
71. Moskowitz AJ, Moskowitz CH. Controversies in the treatment of lymphoma with autologous transplantation. Oncologist 2009 Sep; 14 (9): 921-9
72. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010 Feb; 45 (2): 219-34
73. Moreau P, Avet-Loiseau H, Harousseau J-L, et al. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011 May 10; 29 (14): 1898-906
74. Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009 Oct; 23 (10): 1904-12
75. Mohty M, Duarte RF, Croockewit S, et al. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 2011 Jan; 25 (1): 1-6
76. Jantunen E, Kvalheim G. Mobilization strategies in hardto-mobilize patients with lymphoid malignancies. Eur J Haematol 2010 Dec; 85 (6): 463-71
77. Hicks ML, Lonial S, Langston A, et al. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion (Paris) 2007 Apr; 47 (4): 629-35 (Pubitemid 46449623)
78. Limat S, Woronoff-Lemsi MC, Milpied N, et al. Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. Eur J Cancer 2000 Dec; 36 (18): 2360-7
79. Solá C, Maroto P, Salazar R, et al. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999; 4 (3): 195-209 (Pubitemid 30011407)
80. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheralblood stem cells. J Clin Oncol 1995 Oct; 13 (10): 2547-55
81. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995 Nov 15; 86 (10): 3961-9
82. Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998 May 1; 91 (9): 3148-55 (Pubitemid 28193863)
83. Basak GW, Jaksic O, Koristek Z, et al. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol 2011 Jul; 86 (7): 550-3
84. Dipersio JF, Ho AD, Hanrahan J, et al. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011 Jul; 17 (7): 943-55
85. Hosing C, Smith V, Rhodes B, et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion (Paris) 2011 Jun; 51 (6): 1300-13
86. Jagasia MH, Savani BN, Neff A, et al. Outcome, toxicity profile and cost analysis of autologous stem cell mobilization. Bone Marrow Transplant 2011; 46 (8): 1084-8
87. Gertz MA, Wolf RC, Micallef INM, et al. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010 Sep; 45 (9): 1396-403
88. Tanhehco YC, Adamski J, Sell M, et al. Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs. J Clin Apher 2010; 25 (4): 202-8
89. Duong HK, Bolwell BJ, Rybicki L, et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. J Clin Apher 2011; 26 (3): 111-5
90. Cooper DL, Pratt K, Baker J, et al. Late afternoon dosing of plerixafor for stem cellmobilization: a practical solution.Clin Lymphoma Myeloma Leuk 2011 Jun; 11 (3): 267-72
91. Tornatta J, Maciejewski JJ, Nathan S, et al. Efficacy of administration of plerixafor (Mozobil) at 5:00 PM for stem cell mobilization (SCM) in patients receiving autologous stem cell transplant [abstract no. 3218]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
92. Rosenbaum ER, Nakagawa M, Pesek G, et al. A 15 hour dosing-collection interval for plerixafor is at least as effective as the standard 10 hour interval [abstract no. 2152]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
93. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010 Jan; 45 (1): 39-47
94. Jantunen E, Penttilä K, Pyörälä M, et al. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. BoneMarrow Transplant 2011 Feb; 42 (2): 308-9
95. Jantunen E, Kuittinen T, Mahlamäki E, et al. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011 Apr; 86 (4): 299-304
96. D'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011 Mar; 46 (3): 356-63
97. Basak GW, Mikala G, Koristek Z, et al. Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. Leuk Lymphoma. Epub 2011 Jun 12
98. Kallmeyer C, Anderson S, Anderton P, et al. Use of preemptive plerixafor is successful in reducing mobilisation failure in myeloma patients undergoing PBSC mobilisation with cyclophosphamide and GCSF [poster]. 37th Annual Meeting of the European Group for Bone Marrow Transplantation; 2011 Apr 3-6; Paris
99. Douglas K, Sinclair JE, McQuaker IG, et al. A pro-active approach to plerixafor use and subsequent apheresis can reduce failed autologous PBSC mobilization rates to virtually zero after two mobilization attempts: a single-centre series of 40 consecutive PBSC mobilization episodes using plerixafor in 37 patients [poster]. 37th Annual Meeting of the European Group for Bone Marrow Transplantation; 2011 Apr 3-6; Paris
100. Aabideen K, Anoop P, Ethell ME, et al. The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. J Pediatr Hematol Oncol 2011 Jan; 33 (1): 65-7
101. Flatt T, Lewing K, Gonzalez C, et al. Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent Burkitt lymphoma. Pediatr Hematol Oncol 2010 Mar; 27 (2): 138-49
102. Bernardo VA, Ng JS, Joyce MJ. Use of plerixafor with granulocyte colony-stimulating factor for stem cell mobilization in a pediatric patient. Ann Pharmacother. Epub 2011 Feb
103. Toledano H, Yahel A, Cohen IJ, et al. Successful mobilization, harvest and transplant of peripheral blood stem cells using AMD3100 and G-CSF following high dose craniospinal irradiation for medulloblastoma in a young child. Pediatr Blood Cancer 2010 Apr; 54 (4): 613-5
104. Kobold S, Isernhagen J, Hübel K, et al. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients. Bone Marrow Transplant 2011; 46 (8): 1053-6
105. Tuffaha H, Abdel-Rahman FA. Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor. Hematol Oncol Stem Cell Ther 2010; 3 (4): 203-5
106. Worel N, Apperley J, Basak G, et al. Haematopoietic stem cell mobilization with plerixafor and G-CSF w/wo chemotherapy in patients with non-haematological diseases [poster]. 37th AnnualMeeting of the European Group for Bone Marrow Transplantation; 2011 Apr 3-6; Paris
107. Saure C, Weigelt C, Schroeder T, et al. Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer. Acta Haematol 2010; 124 (4): 235-8
108. Neumann T, Krüger WH, Busemann C, et al. Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone. Bone Marrow Transplant 2011 May; 46 (5): 762-3
109. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008 Aug 15; 112 (4): 990-8
110. Lemery SJ, Hsieh MM, Smith A, et al. A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol 2011 Apr; 153 (1): 66-75
111. Schriber J, Fauble V, Sproat LO, et al. Plerixafor 'just in time' for stem cell mobilization in a normal donor. Bone Marrow Transplant 2011 Jul; 46 (7): 1026-7